Syndax Pharmaceuticals, Inc. (1T3.F)
| Previous close | 20.40 |
| Open | 19.90 |
| Bid | 0.00 x 80000 |
| Ask | 0.00 x 80000 |
| Day's range | 19.90 - 19.90 |
| 52-week range | 10.40 - 22.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 1.715B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.00 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.67 |
Insider MonkeySyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript May 8, 2024 Syndax Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and welcome to the Syndax First Quarter 2024 Earnings Conference Call. Today’s call is […]
PR NewswireSyndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.
- GuruFocus.com
Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Insights into SNDX's robust pipeline progress, financial health, and strategic plans for upcoming drug launches.
